Hydropathic analysis and biological evaluation of stilbene derivatives as colchicine site microtubule inhibitors with anti-leukemic activity

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 24, Issue 6, 2009, Pages 1237-1244

  Tripathi, Ashutosh ^a   Durrant, David ^b   Lee, Ray M ^b   Baruchello, Riccardo ^c   Romagnoli, Romeo ^c   Simoni, Daniele ^c   Kellogg, Glen E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Colchicines; HINT; Hydropathy; Microtubule inhibitors; Stilbene

Indexed keywords

COLCHICINE; COMBRETASTATIN; STILBENE; STILBENE DERIVATIVE; TUBULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; HUMAN; HUMAN CELL; HYDROPATHIC INTERACTION; IN VITRO STUDY; LEUKEMIA CELL; MICROTUBULE; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; COLCHICINE; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; HUMANS; LEUKEMIA; MICROTUBULES; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; TUBULIN MODULATORS;

EID: 73949151167     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756360902787055     Document Type: Article

References (19)

1. World Health Organization. Fact Sheet (Cancer) No.297 Available at http://www.who.int/mediacentre/factsheets/fs297/en/index. html.
2. American Cancer Society. Global Cancer Facts and Figures 2007. Available at http://www.cancer.org
3. Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA. Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 2006;49:3033-3044
4. Bellina F, Cauteruccio S, Monti S, Rossi R. Novel imidazole-based combretastatin A-4 analogues: evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin. Bioorg Med Chem Lett 2006;16:5757-5762
5. Ji Y, Tian R, Lin W. QSAR and molecular docking study of a series of combretastatin analogues tubulin inhibitors. LNCS 2007;4689:436.
6. Belleri M, Ribatti D, Nicoli S, Cotelli F, Forti L, Vannini V, Stivala LA, Presta M. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4?- trimethoxystilbene. Mol Pharmacol 2005;67:1451-1459
7. Cao TM, Durrant D, Tripathi A, Liu J, Tsai S, Kellogg GE, Simoni D, Lee RM. Stilbene derivatives that are colchicine site microtubule inhibitors have anti-leukemic activity and minimal systemic toxicity. Am J Hematol 2008;83:390-397
8. Nogales E, Wolf SG, Downing KH. Structure of the tubulin dimer by electron crystallography. Nature 1998;391:199-203.
9. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev 2004;4:253-265
10. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998;18:259-296
11. Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C, Buscemi F, Grimaudo S, Tolomeo M. Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents. J Med Chem 2003;46:3546-3554
12. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. Insight into tubulin regulation from a complex with colchicine and a stathmin like domain. Nature 2004;428:198-202.
13. Jones G, Willett P, Glen RC, Leach AR, Taylor RJ. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727-748
14. Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, Day BW, Wipf P, Hamel E, Gussio R. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem 2005;48:6107-6116
15. Kellogg GE, Abraham DJ. Hydrophobicity: is LogP(o/w) more than the sum of its parts? Eur J Med Chem 2000;35:651-661
16. Cozzini P, Fornabaio M, Marabotti A, Abraham DJ, Kellogg GE, Mozzarelli A. Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 1. Models without explicit constrained water. J Med Chem 2002;45:2469-2483
17. Spyrakis F, Amadasi A, Fornabaio, M, Abraham DJ, Mozzarelli A, Kellogg GE, Cozzini P. The consequences of scoring docked ligand conformations using free energy correlations. Eur J Med Chem 2007;42:921-933
18. Durrant DE, Richards J, Tripathi A, Kellogg GE, Marchetti P, Eleopra M, Grisolia G, Simoni D, Lee RM. Development of water soluble derivatives of cis-3,4?,5-trimethoxy-3?-aminostilbene for optimization and use in cancer therapy. Invest New Drugs 2009;27:41-52.
19. Tripathi A, Fornabio M, Kellogg GE, Gupton JT, Gewirtz DA, Mooberry SL. Docking and hydropathic scoring of polysubstituted pyrroles compounds with anti-tubulin activity. Bioorg Med Chem 2008;16:2235-2242